Supporting New Treatment Options for Patients With Acute Myeloid Leukemia

Recruiting · Phase 3 · Acute Myeloid Leukemia (AML) · 23 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This clinical trial is looking at a new drug called ziftomenib. It is being tested for people with acute myeloid leukemia (AML) who have specific genetic changes. The goal is to see if adding ziftomenib to standard treatments can improve outcomes for these patients. There are two parts to the study: one for older patients or those with other health issues, and another for medically fit patients.

The trial's ID number is NCT07007312. This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. It is regulated by the FDA, and the study hopes to include about 1,300 participants.

Who can join

This trial is open to adults aged 18 and older. It includes men and women with untreated AML who have certain genetic mutations. Some patients may not qualify if they have specific health problems or have received prior treatments for AML. The trial team will check to confirm if you are eligible to join.

Condition

Acute Myeloid Leukemia (AML)

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be assigned to one of several treatment groups by chance. Some will receive ziftomenib with standard treatments, while others will get a placebo instead of ziftomenib. This ensures that neither the patients nor the doctors know who is receiving the actual treatment. The study has two main groups: one for non-intensive therapy and another for intensive therapy.